All lobbying filings

CROSSROADS STRATEGIES, LLC

Lobbying for SANOFI US SERVICES INC. · pharmaceutical manufacturer

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2026 · New Jersey · House · Senate · $50,000.00 income · posted Apr 19, 2026

Official filing document

Bills named in this filing 2

S 891
Bipartisan Health Care Act
HR 1
An act to provide for reconciliation pursuant to title II of H. Con. Res. 14.

Lobbying activity 6

Health Issues

Issues related to health care, the Food and Drug Administration (FDA), influenza, 340B Program, drug pricing, importation of biopharmaceuticals, international pharmaceutical supply chain, TRICARE Pharmacy Program (FY2027 National Defense Authorization Act), insulin price cap, VICP Program, CICP Program, and PBM reform; vaccine schedule and vaccine safety; Type One Diabetes (T1D) and military healthcare; Pandemic and All-Hazards Preparedness Act (PAHPA) reauthorization; S.891, Bipartisan Health Care Act; Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients Executive Order.

Medicare/Medicaid

General issues related to Medicare and Medicaid, including: Part D Medicare Program; Medicare Part B reimbursement; CMMI Drug Pricing Demonstration Programs; Drug Pricing; Inflation Reduction Act of 2022 (P.L.117-169) implementation.

Biopharmaceutical innovation and patent policy issues. Bayh-Dole march-in rights policy issues.

Trade (domestic/foreign)

Issues related to pharmaceutical IP, supply chain, and tariffs; Section 232 tariff investigation on branded pharmaceuticals.

Taxation/Internal Revenue Code

Issues related to tax reform; R&D tax credit; international taxation; Section 899; H.R.1, One Big Beautiful Bill Act (P.L.119-21) implementation.

Budget/Appropriations

FY2027 Departments of Labor, Health and Human Services, and Education, and Related Agencies Appropriations; issues related to COPD and Type One Diabetes (T1D).

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.